drugset / Trial / NCT02456012

Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients

NCT02456012 ↗

Phase 4 Completed 268 enrolled Hsiu-Chi Cheng
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to determine whether a long-term prophylactic use of esomeprazole 20 mg twice daily or once daily has prevention effectiveness in reducing the recurrence of peptic ulcer bleeding after ulcer healed with 16-week oral esomeprazole therapy in high-risk patients whose Rockall score ≥ 6.

Timeline

Start
2015-04
Primary completion
2020-12-31
Completion
2020-12-31

Outcome

Met primary endpoint

paper For the primary outcome, groups D and S comprised a higher proportion of rebleeding-free than Group C (P = 0.008 and 0.03, log-rank test). PMID 36271335 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg Oral

Indications